缺血性院内卒中患者的溶栓疗效分析

发布时间：2018-06-30 18:51

本文选题：院内卒中 + 溶栓治疗　；参考：《中国神经精神疾病杂志》2017年01期

【摘要】：目的分析缺血性院内卒中(in-hospital stroke,IHS)患者溶栓治疗的疗效。方法收集近5年缺血性IHS患者临床资料,按是否接受重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activato,r-tPA)溶栓治疗分为溶栓组和非溶栓组,比较两组出院时预后良好[改良Rankin量表评分(modified Rankin scale,mRS)0~2分]比例。结果本研究共收集缺血性IHS患者121例,其中溶栓组6例,非溶栓组115例。出院时预后良好(mRS 0~2分)患者溶栓组6例(占100%),而非溶栓组42例(占36.5%),溶栓组预后良好比例显著高于非溶栓组(P0.05)。结论缺血性IHS患者r-tPA溶栓治疗可显著改善临床预后。
[Abstract]:Objective to analyze the effect of thrombolytic therapy in patients with ischemic hospital stroke (in-hospital stroke-IHS). Methods the clinical data of patients with ischemic IHS in recent 5 years were collected and divided into thrombolytic group and non-thrombolytic group according to whether they received recombinant tissue plasminogen activator (recombinant tissue plasminogen activator r-tPA. The ratio of modified Rankin scale score (modified Rankin scale) 0 ~ 2 was compared. Results 121 patients with ischemic IHS were collected, including 6 cases in thrombolytic group and 115 cases in non-thrombolytic group. There were 6 cases (100%) in thrombolytic group and 42 cases (36.5%) in non-thrombolytic group. The rate of good prognosis in thrombolytic group was significantly higher than that in non-thrombolytic group (P0.05). Conclusion r-tPA thrombolytic therapy can significantly improve the clinical prognosis in patients with ischemic IHS.
【作者单位】：暨南大学附属第一医院神经内科和脑血管病中心;解放军第四五八医院神经内科;中山大学附属第一医院神经内科;
【基金】：国家自然科学基金(编号:81171084) 广东省自然科学基金(编号:2014A030313384) 广东省医学科研基金(编号:A2014381) 广州市科技计划(编号:2014Y2-00505、201508020004)
【分类号】：R743.3

【相似文献】